Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Jiangsu Lianhuan Pharmaceutical Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥21 Mil. Jiangsu Lianhuan Pharmaceutical Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-8 Mil.
Jiangsu Lianhuan Pharmaceutical Co's interest coverage for the quarter that ended in Mar. 2026 was 2.53.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Jiangsu Lianhuan Pharmaceutical Co Ltds earnings cannot cover its interest expense. If the situation continues, the company may have to issue more debt.
The historical rank and industry rank for Jiangsu Lianhuan Pharmaceutical Co's Interest Coverage or its related term are showing as below:
SHSE:600513'
s Interest Coverage Range Over the Past 10 Years
Min: 0.64 Med: 9.54 Max: 21.51
Current: 0.64
SHSE:600513's Interest Coverage is ranked worse than 96.06% of 686
companies
in the Drug Manufacturers industry
Industry Median: 12.645
vs SHSE:600513: 0.64
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Jiangsu Lianhuan Pharmaceutical Co Interest Coverage Related Terms
Jiangsu Lianhuan Pharmaceutical Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Jiangsu Lianhuan Pharmaceutical Co Interest Coverage Chart
SHSE:600513 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Lianhuan Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Lianhuan Pharmaceutical Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Lianhuan Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Jiangsu Lianhuan Pharmaceutical Co's Interest Coverage falls into.
Jiangsu Lianhuan Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Interest Coverage of 2.53 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. This is 73% below median its historical median of 9.54. Over the past decade, Jiangsu Lianhuan Pharmaceutical Co's Interest Coverage has ranged from 0.64 to 21.51. According to the industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #659 out of 686 companies in the Drug Manufacturers industry, placing it in the top 96.1%.
Is Jiangsu Lianhuan Pharmaceutical Co's Interest Coverage too high?
Jiangsu Lianhuan Pharmaceutical Co's current Interest Coverage of 2.53 is 73% below median its 10-year median of 9.54. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 21.51. The Drug Manufacturers industry median Interest Coverage is 12.65. Jiangsu Lianhuan Pharmaceutical Co's value of 2.53 is 80% below this industry median. Based on the distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #659 out of 686 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #659 out of 686 companies for Interest Coverage. This places Jiangsu Lianhuan Pharmaceutical Co in the lower half of its industry. The industry median Interest Coverage is 12.65. Jiangsu Lianhuan Pharmaceutical Co's value of 2.53 is 80% below this benchmark. Historically, Jiangsu Lianhuan Pharmaceutical Co's own Interest Coverage has ranged from 0.64 to 21.51 over the past decade. While the company's 10-year median is 9.54 vs. the industry median of 12.65, Jiangsu Lianhuan Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.65, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Lianhuan Pharmaceutical Co's current Interest Coverage of 2.53 is 80% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Lianhuan Pharmaceutical Co's current Interest Coverage is 2.53, which is 73% below median its own 10-year median of 9.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥13.72, compared to a current price of ¥15.42 — trading 12.4% above its estimated fair value. The current Interest Coverage is 2.53, which is 73% below median its 10-year median of 9.54 and 80% below the Drug Manufacturers industry median of 12.65. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Interest Coverage is 2.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥15.42 is trading 12.4% above its estimated GF Value™ of ¥13.72.
GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:600513:
Interest Coverage: 2.53 (73% below median its 10-year median of 9.54)
GF Value™: ¥13.72 vs. price of ¥15.42 (12.4% above fair value)
Industry Position: 80% below the Drug Manufacturers median (#659 of 686)
No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Lianhuan Pharmaceutical Co Business Description
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
65GF Score
Get the complete analysis for SHSE:600513
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600513 has been successfully added to your 
